PremiumCompany AnnouncementsShanghai Henlius Initiates Japanese Study for Cancer Treatment Shanghai Henlius Biotech Initiates Phase 2 Study of HLX43 for Lung Cancer Shanghai Henlius Biotech Gains Approval for H Share Full Circulation PremiumCompany AnnouncementsShanghai Henlius Partners with Sandoz for Global Commercialization of HLX13 Shanghai Henlius Biotech Advances Phase 3 Trial for Cancer Treatment Shanghai Henlius Biotech Partners with Alvogen Korea for Cancer Drug Commercialization PremiumCompany AnnouncementsShanghai Henlius Biotech’s HLX11 Biosimilar Gains EMA Validation Shanghai Henlius Advances Phase 3 Trial of HLX22 in Japan Shanghai Henlius Biotech Advances in Autoimmune Treatment with Phase 2 Trial Approval